• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»microbiome therapeutics

Can Vedanta Biosciences turn microbiome therapeutics into a real prevention strategy for recurrent CDI and resistant infections?

By Pallavi Madhiraju on April 12, 2026   Pharma & Biotech  

Can Vedanta Biosciences turn microbiome therapeutics into a real prevention strategy for recurrent CDI and resistant infections?

Vedanta Biosciences unveiled VE303 and VE707 data at ESCMID 2026. Read why the microbiome strategy matters for CDI and resistant infections.

Vedanta Biosciences keeps VE303 Phase 3 trial on track as interim review clears futility bar

By Pallavi Madhiraju on April 3, 2026   Pharma & Biotech  

Vedanta Biosciences keeps VE303 Phase 3 trial on track as interim review clears futility bar

Vedanta Biosciences kept VE303 Phase 3 on track after interim review. Read what this means for recurrent C. difficile treatment and microbiome drug development.

Why MaaT Pharma’s MaaT013 survival signal could reshape refractory GI-aGvHD treatment debate

By Pallavi Madhiraju on March 24, 2026   Pharma & Biotech  

Why MaaT Pharma’s MaaT013 survival signal could reshape refractory GI-aGvHD treatment debate

MaaT Pharma’s MaaT013 posted pivotal Phase 3 GI-aGvHD data. Read what it could mean for EMA approval, adoption, and microbiome therapeutics.

Recent Posts

  • AACR 2026: SAGA Diagnostics pushes Pathlight MRD deeper into metastatic breast and ovarian cancer
  • Agenus AACR 2026 data show immune reprogramming signal in PD-1 refractory gastroesophageal cancer
  • AACR 2026: Can Zai Lab’s zocilurtatug pelitecan change the treatment picture for small cell lung cancer brain metastases?
  • How JANX014 expands Janux Therapeutics’ tumor-activated platform strategy in prostate cancer immunotherapy
  • What Medicus Pharma Ltd.’s SkinJect application signals for Hedgehog pathway-driven cancers
  • Why Bioxodes’ adaptive trial strategy could accelerate approval timelines in stroke therapeutics
  • What Kura Oncology’s latest data reveals about resistance biology in kidney cancer
  • Can Fate Therapeutics, Inc. solve the conditioning chemotherapy problem in CAR T?
  • Could Ampligen become a late-stage pancreatic cancer breakthrough after AIM ImmunoTech’s latest clinical push?
  • What the new J-code means for Glaukos’ Epioxa launch and the future of keratoconus reimbursement
  • Molgramostim review pushed to November: what Savara’s FDA delay means for autoimmune PAP
  • What SurGenTec’s TiLink navigation clearance means for surgeons using minimally invasive SI joint fusion systems
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes